Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Relay Therapeutics, Inc. RLAY
$10.33
-$0.03 (-0.29%)
На 18:02, 12 мая 2023
+171.06%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1301018670.00000000
-
week52high
33.06
-
week52low
10.40
-
Revenue
1381000
-
P/E TTM
-5
-
Beta
1.31917100
-
EPS
-2.62000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Buy | Buy | 18 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 09 авг 2022 г. |
| Jefferies | Underperform | 06 июн 2022 г. | |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 10 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 14 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 сент 2022 г. |
| Stifel | Buy | 02 сент 2022 г. | |
| Barclays | Equal-Weight | 30 сент 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rahmer Peter | D | 158540 | 740 | 30 янв 2023 г. |
| Bergstrom Donald A | D | 244847 | 1429 | 30 янв 2023 г. |
| Catinazzo Thomas | D | 150482 | 864 | 30 янв 2023 г. |
| Adams Brian | D | 136092 | 864 | 30 янв 2023 г. |
| Patel Sanjiv | D | 610779 | 28000 | 19 янв 2023 г. |
| Patel Sanjiv | D | 254554 | 28000 | 19 янв 2023 г. |
| Patel Sanjiv | A | 282554 | 28000 | 19 янв 2023 г. |
| Patel Sanjiv | D | 638779 | 28000 | 18 янв 2023 г. |
| Patel Sanjiv | D | 254554 | 28000 | 18 янв 2023 г. |
| Patel Sanjiv | A | 282554 | 28000 | 18 янв 2023 г. |
Новостная лента
Relay Therapeutics: Tall Claims, Some Proofs Of Concept, Some Concerns
Seeking Alpha
18 янв 2023 г. в 20:23
Relay Therapeutics, Inc. discovers drugs using a novel computational approach. There is some proof of concept data.
Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?
Zacks Investment Research
13 янв 2023 г. в 12:48
Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:30
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 2:15 p.m. PT. The presentation will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the presentation.
Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
03 ноя 2022 г. в 20:21
Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics: Best-In-Class Potential PIKCA Mutation Inhibitor
Seeking Alpha
30 окт 2022 г. в 14:07
Relay Therapeutics' RLY-2608 is the first pan-allosteric PIKCA mutation inhibitor and has shown promise in preclinical studies, including better safety vs. Piqray (competition). Phase 1 dose escalation data for RLY-2608 is expected in the first half of 2023. The product candidate has the potential to be a blockbuster drug.